Clinical trials: Advanced Tumor
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA
ARTemIS-Eso is a phase I-II, three-level, open-label trial with a dose-expansion cohort at recommended schedule in both esophageal cancer histological groups (squamous cell carcinoma and adenocarcinoma) of RCT and ImT…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Squamous Cell Carcinoma of the Esophagus
- Trial name
- ARTEMIS-Eso (NCT03307941)
- Testing
- Monalizumab, Oxaliplatin, 5-Fluorouracil
- Where
- Belgium
- Sponsor
- Jules Bordet Institute
Advanced Solid Malignancies
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that…
- Trial name
- CERTIS1 (NCT05417594)
- Testing
- AZD9574, Temozolomide (TMZ), [11C]AZ1419 3391
- Where
- 32 sites in United States, Australia and 5 more
- Volunteers
- 695 people
- Sponsor
- AstraZeneca
Advanced Metastastic Malignant Melanoma, Refractory to First-Line Chemotherapy Irresectable Progressive Soft Tissue Metastases
Efficacy of Chemotherapy Combined With Regional Hypothermia in Advanced Malignant Melanoma Patients With Progressive Soft Tissue Metastases
The incidence of malignant melanoma continues to rise throughout the world. Approximately 12 in 100,000 Germans are diagnosed with malignant melanoma per year.
- Trial name
- NCT00264056
- Testing
- hyperthermia
- Where
- Germany
- Volunteers
- 26 people
- Sponsor
- Fachklinik Hornheide an der Universität Münster
Targeted Therapy, Chemotherapy
Donafenib for Recurrent Cervical Cancer
This study is to evaluate the safety and tolerability of Donafenib combined with paclitaxel and platinum ± programmed death 1 monoclonal antibody (PD-1 antibody) in patients with recurrent cervical cancer.
- Conditions
- Targeted Therapy, Chemotherapy, Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma
- Trial name
- NCT05310331
- Testing
- Donafenib combined with paclitaxel and platinum ± PD-1 antibody
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Lei Li
Advanced Solid Tumors
A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.
The goal of this interventional study is to evaluate the safety and tolerability of escalating doses of FORX-428 as monotherapy in patients with select advanced solid tumors with BRCA1/2 mutations or other DDR deficiencies or…
- Trial name
- NCT07356453
- Testing
- FORX-428
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- FoRx Therapeutics AG
Esophageal Squamous Cell Carcinoma, Chemoradiation
Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC
This clinical trial has two stages: phase II and phase III. Eligible patients will be randomized 1:1 to the two arms: paclitaxel plus cisplatin and cisplatin plus 5-fluorouracil.
- Trial name
- NCT03623737
- Testing
- neoadjuvant chemoradiation
- Where
- Taiwan
- Volunteers
- 248 people
- Sponsor
- National Taiwan University Hospital
Cholangiocarcinoma
Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma
The incidence of cholangiocarcinoma is high, the radical resection rate is low, the postoperative recurrence is easy, the prognosis is poor.Gemcitabine combined with cisplatin (GC) is the standard first-line treatment for…
- Trial name
- NCT05697237
- Testing
- Carrelizumab, Solfantinib
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
The goal of this study is to determine the feasibility of administration of a single dose of E7 TCR-T cells as induction therapy prior to definitive treatment (chemoradiation or surgery) of locoregionally advanced HPV-associated…
- Conditions
- HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT05639972
- Testing
- E7 TCR-T cells, Aldesleukin
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Christian Hinrichs
Advanced Pancreatic Cancer
A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer
This is a randomized, double-blind, multi-center, phase III study to evaluate the efficacy and safety, pharmacokinetic profile and immunogenicity of MRG004A in patients with advanced pancreatic cancer.
- Trial name
- NCT07138846
- Testing
- MRG004A plus best supportive care
- Where
- China
- Volunteers
- 231 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Cancer
Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies
JTX-4014-101 is a Phase 1, open label, dose escalation clinical study of JTX-4014 in adult subjects with advanced refractory solid tumor malignancies, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose…
- Trial name
- NCT03790488
- Testing
- JTX-4014
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Jounce Therapeutics, Inc.
Cervical Cancer, Cervix Cancer
Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer
Cervical cancer is the second-most common cancer in the world and is a leading cause of cancer death among women in developing countries.
- Conditions
- Cervical Cancer, Cervix Cancer, Cervix Neoplasm
- Trial name
- NCT04651127
- Testing
- Toripalimab + Chidamide
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Sun Yat-sen University
Advanced or Metastatic Breast Cancer
A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database
The purpose of this real-world study is to look at breast cancer patients receiving Palbociclib using a large real-world database collected under real-world practice.
- Trial name
- NCT06962969
- Testing
- Ibrance
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Breast Cancer
PEAK PlasmaBlade™ 4.0 Versus Traditional Electrosurgery in Lumpectomy
The purpose of this clinical study is to quantify the difference in thermal injury depth at the surgical margin in breast lumpectomy specimens excised with the PlasmaBlade; to subjectively assess histopathologic sample quality…
- Trial name
- PRECISE (NCT00960154)
- Testing
- PEAK PlasmaBlade, Traditional Electrosurgery with scalpel
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Medtronic Surgical Technologies
Advanced Cancer
Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer
After the fourth protocol amendment two study arms are evaluated in this clinical protocol: PD-0325901 (oral MEK inhibitor) plus PF-05212384 (intravenous PI3K/mTOR inhibitor) and PF-05212384 plus irinotecan.
- Trial name
- NCT01347866
- Testing
- PF-05212384, PD-0325901, irinotecan
- Where
- 18 sites in United States, Canada and 2 more
- Volunteers
- 105 people
- Sponsor
- Pfizer
HER2-positive Advanced Breast Cancer
T-DM1 Combined With CDK4/6 Inhibitor Ribociclib
To explore the efficacy and safety of T-DM1 combined with CDK4/6 inhibitor Ribociclib in the treatment of HER2-positive advanced breast cancer.
- Trial name
- NCT06481956
- Testing
- Ribociclib Oral Tablet
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zheng Yabing
Esophageal Squamous Cell Carcinoma
SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer
Patients with previously untreated advanced or metastatic esophageal squamous cell carcinoma are recruited to this prospective non-randomized study comprising two separate cohorts.
- Trial name
- NCT03603756
- Testing
- SHR-1210, Apatinib, Irinotecan Injection
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Chinese Academy of Medical Sciences
Tumor, Ovarian Cancer
Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer
This is a multicenter, open-label, two-arm, 2-stage, Phase 2 study of NKTR-102 in patients with metastatic or locally advanced platinum-resistant ovarian cancer.
- Trial name
- NCT00806156
- Testing
- NKTR-102 q14d, NKTR-102 q21d
- Where
- 20 sites in United States, Belgium and 1 more
- Volunteers
- 178 people
- Sponsor
- Nektar Therapeutics
Head and Neck Cancer
High-Dose Radiation Therapy Plus Chemotherapy in Treating Patients With Advanced Nose or Throat Cancer
RATIONALE: Radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00052429
- Testing
- cisplatin, fluorouracil, adjuvant therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer
This phase II trial is studying how well ixabepilone works in treating patients with metastatic, recurrent, or unresectable kidney cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00182702
- Testing
- ixabepilone, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer, Nonsmall Cell
Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC
Patient selection: a) Pathological confirmation of non-small cell lung cancer without activating EGFR mutations; b) Advanced stage disease (IV or IIIB with malignant effusion) with at least two prior chemotherapy regimens; c) No…
- Trial name
- NCT02991651
- Testing
- IRX4204, erlotinib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Io Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.